News

Accelr8 Announces Independent Study Presentations and New Rapid ESBL Test

DENVER-(Business Wire)-September 4, 2008 - Accelr8 Technology Corporation (Amex: AXK) announced today that the company and its research collaborators have completed two studies that characterize technical advances for its BACcel™ rapid diagnostic system. The system is being developed to rapidly identify bacteria and their antibiotic resistance mechanisms. Targeted organisms include multi-drug resistant organisms or so-called “superbugs” such as MRSA, Pseudomonas, Acinetobacter, and Klebsiella.

Investigators at the Denver Health Medical Center conducted one of the studies. They reviewed the charts of patients who had contracted “Staph” infections, and analyzed the appropriateness of initial treatments prescribed in each case. They analyzed stored bacterial isolates from the same cases, using the BACcel system. “What-if” scenarios projected possible differences in therapy had the BACcel system’s same-day results been available, rather than having to wait 2-3 days for cultures. The projected result would have made a significant improvement in treatment appropriateness, attributable to the system’s speed and accuracy. The investigators will present full details at the joint sessions of the 48^th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (www.icaac.org) and the Infectious Diseases Society of America (www.idsociety.org), October 25-28 in Washington, DC.

The second study used the BACcel system to identify a multi-resistant mechanism known as “ESBL,” which includes hundreds of variant enzymes that break down members of the largest class of antibiotics. ESBLs occur in a large family of bacteria that account for approximately 25% to 35% of serious hospital infections. The bacteria include organisms such as E. coli and Klebsiella. Rapid tests for ESBLs do not exist. The new test takes less than 4 hours, and adds the second of three major pathogen and resistance categories to the BACcel system. The company’s scientists will present results at the ICAAC/IDSA joint sessions in October.

The new ESBL test joins two tests designed for “Staph” infections that the company had previously presented. Accelr8 also plans to add a third category of highly resistant bacteria that includes Pseudomonas and Acinetobacter. This last category accounts for as many as one-third of dangerous ICU infections that are difficult to diagnose and treat.

According to David Howson, Accelr8’s president, “the new results support the promise of the BACcel system as the first platform to cover all of the most dangerous bacteria in the hospital. The system is proving able to report results within the first few hours, which we believe is necessary to help improve outcomes for critically ill patients. We are on plan for developing the additional tests needed for the first ICU test panel.” Howson also noted that the company is on track for meeting its milestones in the technical development project announced in May.

Learn more about Accelr8 and the BACcel system at the company’s Web site, www.accelr8.com.

Certain statements in this news release may be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements regarding future prospects and developments are based upon current expectations and involve certain risks and uncertainties that could cause actual results and developments to differ materially from the forward-looking statement, including those detailed in the company's filings with the Securities and Exchange Commission. Accelr8 does not undertake an obligation to publicly update or revise any forward-looking statements, whether as a result of new information or future events.

Send this news item to a friend.

Print This Page